London, UK – 19 June 2023. Frank Misselwitz, Chief Medical Officer at Actimed Therapeutics, presented on the non-clinical and clinical development of our lead candidate S-pindolol benzoate for the treatment of cancer cachexia at 16th International Conference of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) in Stockholm, Sweden.

This annual high-level congress is hosted by SCWD in partnership with leading research institutes. It brings together experts from around the globe to share insights, research, and innovative ideas related to sarcopenia, cachexia and wasting disorders, fostering collaboration and knowledge exchange across various disciplines.
 
Cancer cachexia is a substantial burden to advanced cancer patients, and remains a significant unmet medical need. The presence of cachexia in any cancer type is associated with reduced physical function, poor mortality outcomes and a poorer prognosis when compared to patients with no weight loss^1,2.
 
After successful in vitro differentiation of S-pindolol versus R-pindolol, and a promising clinical proof-of-concept study, the ACT-ONE study, Actimed is now planning Phase 2b/3 studies (the IMPACT programme) evaluating S-pindolol benzoate for the treatment of cachexia in advanced NSCLC and CRC patients with the aim to make this the first globally approved product for cancer cachexia.

¹ Dewys WD et al., Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69(4):491-97
² Del Fabbro E, Inui A, Strasser F., Cancer Cachexia. Pocket book for cancer supportive care. Springer Healthcare 2012